Key result
Tyramine-induced neuronal noradrenaline release caused an immediate increase in total peripheral vascular resistance that was 4.5 times greater in spontaneous hypertensive rats than normotensive controls.
Why the study?
Does nitric oxide counteract the alpha-adrenergic rise in total peripheral vascular resistance in spontaneous hypertensive rats?
Does nitric oxide counteract the alpha-adrenergic rise in total peripheral vascular resistance in spontaneous hypertensive rats?
In spontaneous hypertensive rats, the alpha1-adrenoceptor response to noradrenaline is increased, but this is strongly counteracted by increased nitric oxide derived from both endothelial and neuronal NOS.
Exaggerated resistance response in hypertensive rats is hypothesis-generating; leaves open nitric oxide counter-regulation of alpha-adrenergic tone in patients.
OBJECTIVE: The hypertension in spontaneous hypertensive rats (SHR) may result from a hyperactive sympathetic nervous system or from insufficient bioactive nitric oxide (NO) due to increased oxidative stress. The present investigation aimed to elucidate the balance between these two systems by studying the ability of NO to oppose an adrenergic rise in total peripheral vascular resistance (TPVR). METHODS: In anesthetized, open-chest SHR and normotensive controls (WKY) on a respirator, blood pressure was recorded in the femoral artery and cardiac output measured by ascending aorta flow. Tyramine infusion (15 min, intravenously) was used to stimulate neuronal noradrenaline release. RESULTS: Tyramine induced an immediate but transient increase in TPVR, which was 4.5 times greater in SHR. After the non-selective NO synthase (NOS) inhibitor (L-NAME: N(omega)-nitro-L-arginine methyl ester), DeltaTPVRimm was 8.6 and 5.3 times increased in SHR and WKY, respectively, and TPVR remained elevated throughout the infusion period. Addition of alpha1-adrenoceptor antagonist (prazosin+L-NAME) abolished the TPVR response to tyramine. Neuronal NOS inhibitor (7-introindazole) increased DeltaTPVRimm only in SHR (2.1 times), and TPVR remained elevated. Inducible NOS inhibitor (1400W), free radical scavenger (tempol), NAD(P)H oxidase inhibitor (apocynin), angiotensin AT1 receptor antagonist (losartan), and ganglion blocker (hexamethonium) had no effect on the tyramine TPVR response in either strain. DeltaTPVR to hexamethonium, prazosin, and L-NAME were greater in SHR than WKY, and hexamethonium reduced DeltaTPVR to L-NAME in SHR only. CONCLUSIONS: The alpha1-adrenoceptor TPVR response to endogenous noradrenaline release was increased in SHR. This was not due to reduced bioavailable NO; on the contrary, NO counteraction was greatly increased, derived from endothelial NOS, with an additional role of neuronal NOS not seen in WKY. An influence of oxidative stress on these responses was not detected in either strain. In addition, a central eNOS sympathoinhibitory component appeared to influence baseline TPVR in SHR.
No takes yet. Share an insight, caveat, or question.
Trond Berg (2005) studied Hypertension. Tyramine infusion vs. Normotensive controls (WKY) was evaluated on Total peripheral vascular resistance (TPVR). Tyramine-induced neuronal noradrenaline release caused an immediate increase in total peripheral vascular resistance that was 4.5 times greater in spontaneous hypertensive rats than normotensive controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: